Investing.com - OncoCyte reported on Thursday third quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.
OncoCyte announced earnings per share of $-0.080 on revenue of $1M. Analysts polled by Investing.com anticipated EPS of $-0.110 on revenue of $1.65M.
OncoCyte shares are down 28.35% from the beginning of the year , still down 83.24% from its 52 week high of $3.58 set on Wednesday, November 10, 2021.
OncoCyte shares gained 5.00% in after-hours trade the report.
OncoCyte follows other major Healthcare sector earnings this month
OncoCyte's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.89B, compared to forecasts EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, compared to forecast for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar